WHO Sounds Alert Over Severe Shortage of Obesity Jabs
Under a tenth of individuals that would benefit from weight-loss injections including Wegovy can access them, states the World Health Organization as it issues its inaugural advice on the therapies.
Given over a billion people worldwide currently living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on forecasts, more than two billion could be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that obesity is a lifelong illness that can be managed with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major hurdles to broad access to the jabs that can assist patients in reducing significant weight, notes the agency.
GLP-1 Therapy Shortage
Even in the current most favorable scenario, the production of such drugs would only suffice for around 100 million people – under 10% of the global need, as stated by the health organization.
The guideline calls on governments and firms to increase availability, through measures including voluntary licensing.
The intellectual property rights on semaglutide – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Function
The injections replicate a natural hormone to reduce digestion speed, curb appetite and enhance satiety so people eat less.
Individuals usually see weight reduction within a few weeks of commencing the weekly injections.
Studies suggests patients may regain a significant portion a year later of halting the treatment, because their normal appetite resume.
To be overweight or obese raises your likelihood for experiencing medical conditions, like type 2 diabetes, heart disease, stroke, and certain cancers.
Excess weight affects people in all nations and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
